Aminoglutethimide and prostatic cancer

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Gynecologic oncology·2019

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.

Familial cancer·2017

Patient-reported outcomes in ovarian cancer clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.

Breast cancer research and treatment·2011

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.

Familial cancer·2011

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Notoginsenoside R1 Alleviates Acetaminophen-Induced Liver Injury via MAPK/mTOR-Mediated Autophagy.

The American journal of Chinese medicine·2026

Tryptophan-Mediated Sodium Dodecyl Sulfate Binding to Proteins.

The protein journal·2026

Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators.

Acta pharmacologica Sinica·2026

Promiscuity of Cytochrome P450 Enzymes: Discovery Strategies, Mechanistic Insights, and Applications in Terpenoid Biosynthesis.

Journal of agricultural and food chemistry·2026

Topical Sirolimus Therapy for Agminated Pyogenic Granulomas: A Two-Case Report.

Pediatric dermatology·2026

HELM-BERT: Topology-Aware Representations for Chemically Modified Peptides.

Journal of chemical information and modeling·2026

Related Experiment Videos

Aminoglutethimide and prostatic cancer

Related Concept Videos

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.

Patient-reported outcomes in ovarian cancer clinical trials.

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Notoginsenoside R1 Alleviates Acetaminophen-Induced Liver Injury via MAPK/mTOR-Mediated Autophagy.

Tryptophan-Mediated Sodium Dodecyl Sulfate Binding to Proteins.

Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators.

Promiscuity of Cytochrome P450 Enzymes: Discovery Strategies, Mechanistic Insights, and Applications in Terpenoid Biosynthesis.

Topical Sirolimus Therapy for Agminated Pyogenic Granulomas: A Two-Case Report.

HELM-BERT: Topology-Aware Representations for Chemically Modified Peptides.

Related Experiment Videos

Aminoglutethimide and prostatic cancer

Related Concept Videos

Related Articles